항감염제 시장 : 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the anti-infective drugs market size in 2026 is estimated at USD 142.46 billion, growing from 2025 value of USD 138.57 billion with 2031 projections showing USD 163.63 billion, growing at 2.81% CAGR over 2026-2031.

This report is Segmented by Drug Class (Antibiotics, Antivirals, Antifungals, Antiparasitics), Indication (HIV Infection, Pneumonia, and More), Route of Administration (Oral, Parenteral, and More), Distribution Channel (Hospital Pharmacy, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Anti-Infective Drugs Market Trends and Insights

Rising Burden of Infectious Diseases

Sepsis-linked inpatient stays, costs and mortality continue to rise in most healthcare systems, magnifying demand for reliable anti-infective regimens. Older adults and immunocompromised patients now present more frequently with severe infections that require prompt, broad-spectrum cover, lengthening inpatient admissions and driving average lengths of stay above pre-pandemic levels. Heightened disease prevalence has stimulated investment in AI-enabled rapid-diagnostic platforms that can shave hours off identification times, thus enabling earlier and more targeted therapy. Global policymakers channel resources toward community-based infection programs that serve disadvantaged groups, helping shape decentralized treatment models in the anti-infective drugs market. The net effect is an enduring demand baseline that offsets price erosion in traditional molecules and anchors volume growth even in mature economies.

Growing Resistance Among Pathogens

Hyper-resistant strains of Klebsiella pneumoniae and Acinetobacter baumannii now circulate across hospitals worldwide, lifting carbapenem resistance to 31.3% in Asia-Pacific and prompting urgent shifts toward B-lactam/B-lactamase inhibitor combinations. Pharmaceutical pipelines increasingly prioritize mechanisms that impede resistance emergence, such as dual-binding site antibiotics that raise mutation barriers by several orders of magnitude. Economic implications are material: resistant infections lengthen hospital stays and require costlier diagnostics, diluting payer budgets and forcing value-based price negotiations. Geographic variation is pronounced; South Asia leads global resistance curves, whereas nitrofurantoin remains broadly effective against urinary isolates in North America and Western Europe. Heightened surveillance and incentives for novel mode-of-action molecules create fresh revenue headroom for innovators within the anti-infective drugs market.

Escalating Antimicrobial Resistance (AMR)

Bedaquiline resistance has already reached 5.7% globally, peaking at 10.4% in South Africa, compressing therapeutic windows for multidrug-resistant tuberculosis. Hospitals report rising vancomycin-resistant Enterococcus and carbapenem-resistant Acinetobacter rates, complicating empiric therapy and elevating mortality. Pharmaceutical firms confront diminishing returns as resistance shortens product life, deterring investment in traditional broad-spectrum classes that once delivered decades of revenue. Payers respond by limiting premium pricing to drugs with demonstrable resistance-suppression properties, constraining top-line prospects for molecules lacking novel mechanisms. The compounding clinical and economic toll moderates the longer-term momentum of the anti-infective drugs market.

Other drivers and restraints analyzed in the detailed report include:

1. Robust R&D Investment & Public-Private Collaborations
2. Advanced Drug Development Technologies
3. Strict Regulatory Environment & Safety Concerns

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Antibiotics delivered a 42.62% market share of the anti-infective drugs market share, as clinical reliance on B-lactams, macrolides, and carbapenems remained heavy in hospital protocols. Persistent resistance and stewardship initiatives, however, have capped volume growth, channeling R&D investment toward next-generation combinations such as aztreonam-avibactam, which gained FDA clearance in February 2025. Antivirals posted the most robust 4.58% CAGR outlook as HIV, RSV, and hepatitis formulations shift to long-acting injectables and antibody cocktails that promise quarterly or semi-annual dosing convenience. That innovation pipeline repositioned the segment as a strategic growth engine inside the anti-infective drugs market.

Breakthrough respiratory antivirals also benefit from pandemic preparedness budgets that bankroll surge capacity and stockpiling. Competitive intensity deepens as brand-name incumbents defend share against biosimilars in mature classes while venture-backed biotech entrants introduce narrow-spectrum bacteriophages. Price-volume dynamics therefore diverge: antibiotics witness modest price erosion offset by large installed volume, whereas antivirals command premium pricing but face smaller treated-patient bases. The interplay sustains overall revenue growth and shapes long-term R&D capital allocation.

HIV therapy retained 27.05% of the anti-infective drugs market size in 2025 thanks to widespread adoption of integrase inhibitor backbones and growing uptake of pre-exposure prophylaxis (PrEP). Lenacapavir's potential annual production cost of USD 40 invites broader LMIC access, underpinning volume stability even as mature Western markets plateau. In contrast, respiratory virus infections are projected to log a 4.38% CAGR as RSV prophylaxis gains momentum following data showing a 78% reduction in infant hospitalizations with nirsevimab.

Tuberculosis remains a major clinical focus, with shorter six-month BPaL/M regimens projected to treat 126,792 patients globally by 2026, shrinking total therapy days and reducing health-system cost burdens. Sepsis protocols that prioritize broad-spectrum coverage within the first hour have driven a 4.9-fold survival benefit, intensifying demand for ready-to-reconstitute injectables in emergency settings. These varied indication trajectories collectively reinforce the anti-infective drugs market diversification, lessening dependence on any single pathogen area.

Complete Report Scope:

• By Drug Class
  • Antibiotics
    • B-lactam & B-lactamase inhibitors
    • Macrolides
    • Tetracyclines
    • Fluoroquinolones
    • Cephalosporins
    • Carbapenems
    • Others
  • Antivirals
    • NRTIs
    • NNRTIs
    • Protease inhibitors
    • Integrase inhibitors
    • Polymerase inhibitors
    • Others
  • Antifungals
    • Azoles
    • Echinocandins
    • Polyenes
    • Allylamines
    • Others
  • Antiparasitics
    • Antimalarials
    • Anthelmintics
    • Antiprotozoals
    • Others
• By Indication
  • HIV Infection
  • Pneumonia
  • Respiratory Virus Infection
  • Sepsis
  • Tuberculosis
  • Urinary Tract Infection
  • Skin & Soft-Tissue Infections
  • Other Indications
• By Route of Administration
  • Oral
  • Parenteral
  • Topical
  • Inhalation
  • Others
• By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Mail-order Pharmacy
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America controlled 33.41% of 2025 revenue through an entrenched innovation ecosystem, dynamic payer mix, and early adoption of novel agents. The FDA's streamlined unmet-need guidance reduces scientific advice cycles, yet heightened post-market study obligations inflate compliance costs that manufacturers must factor into pricing models. U.S. sepsis admissions number 2.5 million annually with aggregate costs of USD 52.1 billion, anchoring steady utilization of broad-spectrum injectables and driving formulary turnover. Canada and Mexico augment the regional footprint by contributing specialized fill-finish capacity that feeds northbound and southbound trade flows, though divergent pharmaceutical price controls remain a commercial consideration.

Europe exhibits a unified strategic stance against AMR. Revised EU pharmaceutical legislation harmonizes resistance-monitoring requirements, enabling companies to file a single surveillance plan for all member states. Public-private alliances exemplified by the GSK-UK AMR program demonstrate how shared-risk funding accelerates late-stage antibiotic candidates. However, austerity in Southern Europe constrains reimbursement for premium-priced agents, forcing differential pricing strategies that weigh on pan-European average selling prices. Brexit introduces regulatory bifurcation, with companies navigating dual approval channels to achieve full market reach.

Asia-Pacific is projected to grow at 3.68% CAGR to 2031, making it the fastest-expanding component of the anti-infective drugs market. China dominates global antibiotic active-ingredient output and hosts 20 antibacterial projects across 17 local firms that align with national AMR priorities. India leverages cost-competitive chemistry capabilities but grapples with environmental discharge controls that could raise long-term manufacturing overhead. Japan's expedited approval pathway for high-priority antimicrobials shortens time-to-market by up to 12 months, while Australia funds market-entry rewards for innovative antibiotics to safeguard local supply. Yet, elevated carbapenem resistance 31.3% regional prevalence amplifies clinical urgency and shapes procurement preferences toward agents with robust resistance-suppression data.

1. Abbott Laboratories
2. Astellas Pharma
3. Bayer
4. Bristol-Myers Squibb
5. Gilead Sciences
6. GlaxoSmithKline
7. Merck
8. Novartis
9. Pfizer
10. Sanofi
11. Lupin
12. Dr. Reddy's Laboratories Ltd.
13. Glenmark Pharmaceuticals
14. Johnson & Johnson
15. AstraZeneca
16. Abbvie
17. Cipla
18. Teva Pharmaceutical Industries
19. Sun Pharmaceuticals Industries
20. ViiV Healthcare

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Burden of Infectious Diseases
  • 4.2.2 Growing Resistance Among Pathogens
  • 4.2.3 Robust R&D Investment & Public-Private Collaborations
  • 4.2.4 Advanced Drug Development Technologies
  • 4.2.5 Improved Access Through Stewardship & Global Health Programs
  • 4.2.6 Analytics-Driven Antimicrobial Stewardship Adoption
• 4.3 Market Restraints
  • 4.3.1 Escalating Antimicrobial Resistance (AMR)
  • 4.3.2 Strict Regulatory Environment & Safety Concerns
  • 4.3.3 Global Supply Chain Disruptions
  • 4.3.4 Proliferation of Falsified or Substandard Medicines
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Drug Class
  • 5.1.1 Antibiotics
    • 5.1.1.1 B-lactam & B-lactamase inhibitors
    • 5.1.1.2 Macrolides
    • 5.1.1.3 Tetracyclines
    • 5.1.1.4 Fluoroquinolones
    • 5.1.1.5 Cephalosporins
    • 5.1.1.6 Carbapenems
    • 5.1.1.7 Others
  • 5.1.2 Antivirals
    • 5.1.2.1 NRTIs
    • 5.1.2.2 NNRTIs
    • 5.1.2.3 Protease inhibitors
    • 5.1.2.4 Integrase inhibitors
    • 5.1.2.5 Polymerase inhibitors
    • 5.1.2.6 Others
  • 5.1.3 Antifungals
    • 5.1.3.1 Azoles
    • 5.1.3.2 Echinocandins
    • 5.1.3.3 Polyenes
    • 5.1.3.4 Allylamines
    • 5.1.3.5 Others
  • 5.1.4 Antiparasitics
    • 5.1.4.1 Antimalarials
    • 5.1.4.2 Anthelmintics
    • 5.1.4.3 Antiprotozoals
    • 5.1.4.4 Others
• 5.2 By Indication
  • 5.2.1 HIV Infection
  • 5.2.2 Pneumonia
  • 5.2.3 Respiratory Virus Infection
  • 5.2.4 Sepsis
  • 5.2.5 Tuberculosis
  • 5.2.6 Urinary Tract Infection
  • 5.2.7 Skin & Soft-Tissue Infections
  • 5.2.8 Other Indications
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Parenteral
  • 5.3.3 Topical
  • 5.3.4 Inhalation
  • 5.3.5 Others
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacy
  • 5.4.2 Retail Pharmacy
  • 5.4.3 Online Pharmacy
  • 5.4.4 Mail-order Pharmacy
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 Astellas Pharma Inc
  • 6.3.3 Bayer AG
  • 6.3.4 Bristol-Myers Squibb Co.
  • 6.3.5 Gilead Sciences Inc.
  • 6.3.6 GlaxoSmithKline plc
  • 6.3.7 Merck & Co. Inc.
  • 6.3.8 Novartis AG
  • 6.3.9 Pfizer Inc.
  • 6.3.10 Sanofi SA
  • 6.3.11 Lupin Ltd.
  • 6.3.12 Dr. Reddy's Laboratories Ltd.
  • 6.3.13 Glenmark Pharmaceuticals Ltd.
  • 6.3.14 Johnson & Johnson
  • 6.3.15 AstraZeneca plc
  • 6.3.16 AbbVie Inc.
  • 6.3.17 Cipla Ltd.
  • 6.3.18 Teva Pharmaceutical Industries
  • 6.3.19 Sun Pharma
  • 6.3.20 ViiV Healthcare

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment